

RECEIVED

MAY

TECHNIENT 7 2003

FICE

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT:

D. Williams et al.

SERIAL NO.:

09/506,362

GROUP: 1624

FILED:

February 15, 2000

EXAMINER: J. Ford

FOR:

APOPTOSIS-INDUCING COMPOUNDS

Honorable Commissioner for Patents Washington, D.C. 20231

#### **TRANSMITTAL**

1. Transmitted herewith is an Amendment for this application.

#### **STATUS**

2.	Applicant is				
	[ ]	a small entity. A statement:			
		[ ] is attached.			
		[ ] was already filed.			
	[X]	other than a small entity.			

### **EXTENSION OF TERM**

NOTE: "Extension of Time in Patent Cases (Supplement Amendments) — If a timely and complete response has been filed after a Non-Final Office Action, an extension of time is not required to permit filing and/or entry of an additional amendment after expiration of the shortened statutory period.

If a timely response has been filed after a Final Office Action, an extension of time is required to permit filing and/or entry

## CERTIFICATE OF MAILING/TRANSMISSION (37 C.F.R. 1.8(a))

I hereby certify that, on the date shown below, this correspondence is being:

#### **MAILING**

deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: April 29, 2003

#### **FACSIMILE**

transmitted by facsimile to the Patent and Trademark Office.

dusar on Oullon

Signature

Susan M. Dillon

(type or print name of person certifying)

(Amendment Transmittal—page 1 of 4)

	unless th	ne timely-filed response placed the appl	n additional amendment after expiration of ication in condition for allowance. Of co the period has ceased to run." Notice of	ourse, if a Notice of Appeal has			
NOTE:		37 C.F.R. § 1.645 for extensions of time in interference proceedings, and 37 C.F.R. § 1.550(c) for extensions of time in camination proceedings.					
3.	The proceedings herein are for a patent application and the provisions of 37 C.F.R. § 1.136 apply.						
		(complete (	a) or (b), as applicable)				
	(a)		an extension of time under 37 C.F (a)(1)-(4)) for the total number of the total number	•			
		Extension	Fee for other than	Fee for			
		(months)	small entity	small entity			
	[]	one month	\$ 110.00	\$ 55.00			
	[]	two months	\$ 400.00	\$ 200.00			
	ij	three months	\$ 920.00	\$ 460.00			
	ij	four months	\$ 1,440.00	\$ 720.00			
			Fee: \$				
If an ad	lditional	extension of time is required, ple	ease consider this a petition therefor	or.			
		(check and comple	ete the next item, if applicable)				
	[]		is has already been secured. The fe om the total fee due for the total	=			
		Extension fee due with	this request \$	_			

OR

overlooked the need for a petition for extension of time.

Applicant believes that no extension of term is required. However, this conditional petition is being made to provide for the possibility that applicant has inadvertently

(b)

[X]

### FEE FOR CLAIMS

4. The fee for claims (37 C.F.R. § 1.16(b)-(d)) has been calculated as shown below:

(Col.1)		(Col. 2)	(Col. 3) S	S) SMALL ENTITY		OTHER THAN A SMALL ENTITY		
	Claims							
	Remaining	Highest No.						
After		Previously Present		Addit.				Addit.
	Amendment	Paid For	Extra	Rate	Fee	OR	Rate	Fee
Total	Minus		=	x \$9 =	\$		x \$18 =	\$
Indep.	Minus		=	x \$39 =	\$		x \$78 =	\$
[ ] Firs	st Presentation of Mu	ltiple Depende	nt Claim	+ \$130 =	- \$		+ \$260 =	\$
			<del>_</del>	Total		OR	Total	
				Addit. Fee	\$0.00	1	Addit. Fee	\$
** If t	the entry in Col. 1 is less the "Highest No. Previously th	ly Paid For" IN Th	IIS SPACE	is less than 20, e				

\*\*\* If the "Highest No. Previously Paid For" IN THIS SPACE is less than 3, enter "3".

The "Highest No. Previously Paid For" (Total or Indep.) is the highest number found in the appropriate box in Col. 1 of a prior amendment or the number of claims originally filed.

WARNING: "After final rejection or action (§ 1.113) amendments may be made canceling claims or complying with any requirement of form which has been made." 37 C.F.R. § 1.116(a) (emphasis added).

(complete (c) or (d), as applicable)

(c) [X] No additional fee for claims is required.

OR

(d) [ ] Total additional fee for claims required \$ \_\_\_\_\_.

#### **FEE PAYMENT**

5.	[]	Attached is a check in the sum of \$
	[]	Charge Account No the sum of \$
		A duplicate of this transmittal is attached.

# FEE DEFICIENCY

NOTE: If there is a fee deficiency and there is no authorization to charge an account, additional fees are necessary to cover the additional time consumed in making up the original deficiency. If the maximum, six-month period has expired before the deficiency is noted and corrected, the application is held abandoned. In those instances where authorization to charge is included, processing delays are encountered in returning the papers to the PTO Finance Branch in order to apply these charges prior to action on the cases. Authorization to charge the deposit account for any fee deficiency should be checked. See the Notice of April 7, 1986, (1065 O.G. 31-33).

6. [X] If any additional extension and/or fee is required, charge Account No. <u>04-1105</u>.

### AND/OR

[X] If any additional fee for claims is required, charge Account No. \_\_04-1105\_\_\_\_.

SIGNATURE OF PRACTITIONER

Chine C.M.

Reg. No.38,256 Christ

Tel. No: 617-439-4444

Christine C. O'Day
(type or print name of practitioner)
EDWARDS & ANGELL LLP
P.O. Box 9169
Boston, MA 02209





## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#240

**APPLICANT:** 

D. Williams, et al.

**SERIAL NO.:** 

09/506,362

**ART UNIT: 1624** 

FILED:

February 15, 2000

**EXAMINER:** J. Ford

FOR:

APOPTOSIS-INDUCING COMPOUNDS

Honorable Commissioner of Patents and Trademarks Washington, DC 20231

Sir:

#### **AMENDMENT**

In response to the Office Action issued on January 31, 2003, Applicants kindly request that the application be amended as follows:

## **IN THE CLAIMS:**

Kindly add the following new claim:

- 48. A method of claim 45 wherein the compound is selected from the group consisting of:
- 4-Acetoxy-5-phenylnaphto[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,
- 7-Acetoxy-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzoxazepine,
- 4[(Dimethylcarbamoyl)oxy]-5-phenylnaphto[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,
- 7-[(Dimethylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzoxazepine,
- 7-[(Methylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][1,5]-benzoxazepine,
- 7-[(Dimethylcarbamoyl)oxy]-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzothiazepine,
- 7-Acetoxy-6-(1-naphthyl)pyrrolo[2,1-d][1,5]benzothiazepine,
- 7-Acetoxy-6-(1-naphthyl)pyrrolo[1,2-d]pyrido[3,2-b][1,4]oxazepine,
- 4-Acetoxy-5-(1-naphthyl)naphtho[2,3-b]pyrrolo[1,2-d][1,4]oxazepine,